These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 20160634

  • 1. N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations.
    Radzio J, Yap SH, Tachedjian G, Sluis-Cremer N.
    AIDS; 2010 Mar 13; 24(5):659-67. PubMed ID: 20160634
    [Abstract] [Full Text] [Related]

  • 2. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
    Yap SH, Sheen CW, Fahey J, Zanin M, Tyssen D, Lima VD, Wynhoven B, Kuiper M, Sluis-Cremer N, Harrigan PR, Tachedjian G.
    PLoS Med; 2007 Dec 13; 4(12):e335. PubMed ID: 18052601
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase.
    Parikh UM, Zelina S, Sluis-Cremer N, Mellors JW.
    AIDS; 2007 Jul 11; 21(11):1405-14. PubMed ID: 17589186
    [Abstract] [Full Text] [Related]

  • 5. Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodeficiency virus type 1 reverse transcriptase.
    Frankel FA, Marchand B, Turner D, Götte M, Wainberg MA.
    Antimicrob Agents Chemother; 2005 Jul 11; 49(7):2657-64. PubMed ID: 15980333
    [Abstract] [Full Text] [Related]

  • 6. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
    Marcelin AG, Delaugerre C, Wirden M, Viegas P, Simon A, Katlama C, Calvez V.
    J Med Virol; 2004 Jan 11; 72(1):162-5. PubMed ID: 14635026
    [Abstract] [Full Text] [Related]

  • 7. Thymidine-analog and multi-nucleoside resistance mutations are observed in both zidovudine-naive and zidovudine-experienced subjects with viremia after treatment with stavudine-containing regimens.
    Ross L, Henry K, Paar D, Salvato P, Shaefer M, Fisher R, Liao Q, St Clair M.
    J Hum Virol; 2001 Jan 11; 4(4):217-22. PubMed ID: 11694850
    [Abstract] [Full Text] [Related]

  • 8. Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
    Gupta S, Fransen S, Paxinos EE, Stawiski E, Huang W, Petropoulos CJ.
    Antimicrob Agents Chemother; 2010 May 11; 54(5):1973-80. PubMed ID: 20194692
    [Abstract] [Full Text] [Related]

  • 9. N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations.
    Sluis-Cremer N, Moore K, Radzio J, Sonza S, Tachedjian G.
    AIDS; 2010 Jan 16; 24(2):317-9. PubMed ID: 20010074
    [Abstract] [Full Text] [Related]

  • 10. Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase.
    von Wyl V, Ehteshami M, Symons J, Bürgisser P, Nijhuis M, Demeter LM, Yerly S, Böni J, Klimkait T, Schuurman R, Ledergerber B, Götte M, Günthard HF, Swiss HIV Cohort Study.
    J Infect Dis; 2010 Apr 01; 201(7):1054-62. PubMed ID: 20170373
    [Abstract] [Full Text] [Related]

  • 11. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.
    Parikh UM, Bacheler L, Koontz D, Mellors JW.
    J Virol; 2006 May 01; 80(10):4971-7. PubMed ID: 16641288
    [Abstract] [Full Text] [Related]

  • 12. Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanisms.
    Ehteshami M, Beilhartz GL, Scarth BJ, Tchesnokov EP, McCormick S, Wynhoven B, Harrigan PR, Götte M.
    J Biol Chem; 2008 Aug 08; 283(32):22222-32. PubMed ID: 18547911
    [Abstract] [Full Text] [Related]

  • 13. The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.
    Xu HT, Colby-Germinario SP, Oliveira M, Han Y, Quan Y, Zanichelli V, Wainberg MA.
    J Virol; 2014 Feb 08; 88(3):1536-47. PubMed ID: 24227862
    [Abstract] [Full Text] [Related]

  • 14. Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors.
    Brehm JH, Koontz DL, Wallis CL, Shutt KA, Sanne I, Wood R, McIntyre JA, Stevens WS, Sluis-Cremer N, Mellors JW, CIPRA-SA Project 1 Study Team.
    Clin Infect Dis; 2012 Sep 08; 55(5):737-45. PubMed ID: 22618567
    [Abstract] [Full Text] [Related]

  • 15. Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
    Llibre JM, Bonjoch A, Iribarren J, Galindo MJ, Negredo E, Domingo P, Pérez-Alvarez N, Martinez-Picado J, Schapiro J, Clotet B, HIV Conference Call Study Group.
    HIV Med; 2008 Aug 08; 9(7):508-13. PubMed ID: 18484978
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 Reverse transcriptase facilitates dual resistance to zidovudine and lamivudine.
    Zelina S, Sheen CW, Radzio J, Mellors JW, Sluis-Cremer N.
    Antimicrob Agents Chemother; 2008 Jan 08; 52(1):157-63. PubMed ID: 17967907
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
    Mathiesen S, Dam E, Roge B, Joergensen LB, Laursen AL, Gerstoft J, Clavel F.
    Antivir Ther; 2007 Jan 08; 12(3):335-43. PubMed ID: 17591023
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.